featured
Immunogenicity, Safety, and Tolerability of the Measles-Vectored Chikungunya Virus Vaccine MV-CHIK
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Immunogenicity, Safety, and Tolerability of the Measles-Vectored Chikungunya Virus Vaccine MV-CHIK: A Double-Blind, Randomised, Placebo-Controlled and Active-Controlled Phase 2 Trial
Lancet 2018 Nov 05;[EPub Ahead of Print], EC Reisinger, R Tschismarov, E Beubler, U Wiedermann, C Firbas, M Loebermann, A Pfeiffer, M Muellner, E Tauber, K RamsauerFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.